492 related articles for article (PubMed ID: 32152484)
1. Exploiting the folate receptor α in oncology.
Scaranti M; Cojocaru E; Banerjee S; Banerji U
Nat Rev Clin Oncol; 2020 Jun; 17(6):349-359. PubMed ID: 32152484
[TBL] [Abstract][Full Text] [Related]
2. Folate Receptor α-Targeted
Heo GS; Detering L; Luehmann HP; Primeau T; Lee YS; Laforest R; Li S; Stec J; Lim KH; Lockhart AC; Liu Y
Mol Pharm; 2019 Sep; 16(9):3996-4006. PubMed ID: 31369274
[TBL] [Abstract][Full Text] [Related]
3. Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer.
Bergamini A; Ferrero S; Leone Roberti Maggiore U; Scala C; Pella F; Vellone VG; Petrone M; Rabaiotti E; Cioffi R; Candiani M; Mangili G
Expert Opin Investig Drugs; 2016 Dec; 25(12):1405-1412. PubMed ID: 27797594
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.
Moore KN; Borghaei H; O'Malley DM; Jeong W; Seward SM; Bauer TM; Perez RP; Matulonis UA; Running KL; Zhang X; Ponte JF; Ruiz-Soto R; Birrer MJ
Cancer; 2017 Aug; 123(16):3080-3087. PubMed ID: 28440955
[TBL] [Abstract][Full Text] [Related]
5. Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine.
Martin LP; Konner JA; Moore KN; Seward SM; Matulonis UA; Perez RP; Su Y; Berkenblit A; Ruiz-Soto R; Birrer MJ
Gynecol Oncol; 2017 Nov; 147(2):402-407. PubMed ID: 28843653
[TBL] [Abstract][Full Text] [Related]
6. IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.
Ab O; Whiteman KR; Bartle LM; Sun X; Singh R; Tavares D; LaBelle A; Payne G; Lutz RJ; Pinkas J; Goldmacher VS; Chittenden T; Lambert JM
Mol Cancer Ther; 2015 Jul; 14(7):1605-13. PubMed ID: 25904506
[TBL] [Abstract][Full Text] [Related]
7. The folate receptor as a rational therapeutic target for personalized cancer treatment.
Assaraf YG; Leamon CP; Reddy JA
Drug Resist Updat; 2014; 17(4-6):89-95. PubMed ID: 25457975
[TBL] [Abstract][Full Text] [Related]
8.
Altwerger G; Bonazzoli E; Bellone S; Egawa-Takata T; Menderes G; Pettinella F; Bianchi A; Riccio F; Feinberg J; Zammataro L; Han C; Yadav G; Dugan K; Morneault A; Ponte JF; Buza N; Hui P; Wong S; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
Mol Cancer Ther; 2018 May; 17(5):1003-1011. PubMed ID: 29440294
[TBL] [Abstract][Full Text] [Related]
9. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.
Moore KN; Martin LP; O'Malley DM; Matulonis UA; Konner JA; Perez RP; Bauer TM; Ruiz-Soto R; Birrer MJ
J Clin Oncol; 2017 Apr; 35(10):1112-1118. PubMed ID: 28029313
[TBL] [Abstract][Full Text] [Related]
10. Folate-appended cyclodextrin carrier targets ovarian cancer cells expressing the proton-coupled folate transporter.
Saito S; Koya Y; Kajiyama H; Yamashita M; Kikkawa F; Nawa A
Cancer Sci; 2020 May; 111(5):1794-1804. PubMed ID: 32154964
[TBL] [Abstract][Full Text] [Related]
11. Antibody-drug conjugates for ovarian cancer: current clinical development.
Stewart D; Cristea M
Curr Opin Obstet Gynecol; 2019 Feb; 31(1):18-23. PubMed ID: 30531606
[TBL] [Abstract][Full Text] [Related]
12. Targeting folate receptor alpha for cancer treatment.
Cheung A; Bax HJ; Josephs DH; Ilieva KM; Pellizzari G; Opzoomer J; Bloomfield J; Fittall M; Grigoriadis A; Figini M; Canevari S; Spicer JF; Tutt AN; Karagiannis SN
Oncotarget; 2016 Aug; 7(32):52553-52574. PubMed ID: 27248175
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer.
Yam C; Rauch GM; Rahman T; Karuturi M; Ravenberg E; White J; Clayborn A; McCarthy P; Abouharb S; Lim B; Litton JK; Ramirez DL; Saleem S; Stec J; Symmans WF; Huo L; Damodaran S; Sun R; Moulder SL
Invest New Drugs; 2021 Apr; 39(2):509-515. PubMed ID: 32984932
[TBL] [Abstract][Full Text] [Related]
14. Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models.
Ponte JF; Ab O; Lanieri L; Lee J; Coccia J; Bartle LM; Themeles M; Zhou Y; Pinkas J; Ruiz-Soto R
Neoplasia; 2016 Dec; 18(12):775-784. PubMed ID: 27889646
[TBL] [Abstract][Full Text] [Related]
15. Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level.
Song DG; Ye Q; Poussin M; Chacon JA; Figini M; Powell DJ
J Hematol Oncol; 2016 Jul; 9(1):56. PubMed ID: 27439908
[TBL] [Abstract][Full Text] [Related]
16. Antibody-drug conjugates in gynecologic malignancies.
Lee EK; Liu JF
Gynecol Oncol; 2019 Jun; 153(3):694-702. PubMed ID: 30929824
[TBL] [Abstract][Full Text] [Related]
17. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
O'Malley DM; Matulonis UA; Birrer MJ; Castro CM; Gilbert L; Vergote I; Martin LP; Mantia-Smaldone GM; Martin AG; Bratos R; Penson RT; Malek K; Moore KN
Gynecol Oncol; 2020 May; 157(2):379-385. PubMed ID: 32081463
[TBL] [Abstract][Full Text] [Related]
18. Fischer 344 Rat: A Preclinical Model for Epithelial Ovarian Cancer Folate-Targeted Therapy.
Azaïs H; Queniat G; Bonner C; Kerdraon O; Tardivel M; Jetpisbayeva G; Frochot C; Betrouni N; Collinet P; Mordon S
Int J Gynecol Cancer; 2015 Sep; 25(7):1194-200. PubMed ID: 26244757
[TBL] [Abstract][Full Text] [Related]
19. Farletuzumab, an anti-folate receptor α antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro.
Kamen BA; Smith AK
Cancer Chemother Pharmacol; 2012 Jul; 70(1):113-20. PubMed ID: 22644798
[TBL] [Abstract][Full Text] [Related]
20. Improved Intraoperative Detection of Ovarian Cancer by Folate Receptor Alpha Targeted Dual-Modality Imaging.
Hekman MCH; Boerman OC; Bos DL; Massuger LFAG; Weil S; Grasso L; Rybinski KA; Oosterwijk E; Mulders PFA; Rijpkema M
Mol Pharm; 2017 Oct; 14(10):3457-3463. PubMed ID: 28826214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
